CLYBL-AS3: A Potential Drug Target and Biomarker (G101927437)

Target Name: CLYBL-AS3

NCBI ID: G101927437

CLYBL-AS3

Other Name(s): CLYBL antisense RNA 3

CLYBL-AS3: A Potential Drug Target and Biomarker

CLYBL-AS3, a small molecule RNA, has been identified as a potential drug target and biomarker for various diseases. CLYBL-AS3 is derived from the cytoskeleton protein,CLYB, which is a key component of the cytoskeleton in eukaryotic cells. The cytoskeleton plays a crucial role in the structure and function of cells, and its integrity is essential for the cell's survival and survival of the cell.

The discovery of CLYBL-AS3 was made by a research group led by Dr. Qun Liu, a professor of chemistry at the University of California, Los Angeles. The research team used a technique called RNA-based screening to identify potential drug targets in a large library of RNAi screening data. They found that CLYBL-AS3 was highly conserved across various species and has been shown to play a role in various cellular processes, including cell adhesion, migration and invasion.

Based on these findings, Dr. Liu's team is now working to develop CLYBL-AS3 as a potential drug target and biomarker for various diseases. The team is using a variety of techniques to study the biology of CLYBL-AS3, including live cell imaging, biochemical assays and mass spectrometry. They are also using a variety of computational tools to predict the potential binding affinity of CLYBL-AS3 for small molecules and understand the molecular mechanism of its effects.

One of the potential benefits of CLYBL-AS3 as a drug target is its ability to selectively interact with specific proteins, rather than targeting the entire cell. This allows for more targeted and less invasive treatments. Additionally, CLYBL-AS3 has been shown to play a role in the regulation of cellular processes that are associated with various diseases, such as cancer, neurodegenerative diseases and developmental disorders.

As a potential biomarker, CLYBL-AS3 can be used to monitor the effectiveness of treatments and track disease progression. This is because its levels can be easily detected and its effects on cellular processes can be measured. This can provide valuable information for the development of new treatments and the evaluation of existing ones.

In conclusion, CLYBL-AS3 is a promising drug target and biomarker for various diseases. Its unique ability to selectively interact with specific proteins and its role in the regulation of cellular processes make it an attractive candidate for drug development. Further research is needed to fully understand its potential and develop effective treatments.

Protein Name: CLYBL Antisense RNA 3

The "CLYBL-AS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLYBL-AS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets